Home >> Research Area >> Tirofiban

Tirofiban

CAS# 144494-65-5

Tirofiban

Catalog No. BCC4868----Order now to get a substantial discount!

Product Name & Size Price Stock
Tirofiban: 5mg $115 In Stock
Tirofiban: 10mg Please Inquire In Stock
Tirofiban: 20mg Please Inquire Please Inquire
Tirofiban: 50mg Please Inquire Please Inquire
Tirofiban: 100mg Please Inquire Please Inquire
Tirofiban: 200mg Please Inquire Please Inquire
Tirofiban: 500mg Please Inquire Please Inquire
Tirofiban: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Tirofiban

Number of papers citing our products

Chemical structure

Tirofiban

3D structure

Chemical Properties of Tirofiban

Cas No. 144494-65-5 SDF Download SDF
PubChem ID 60947 Appearance Powder
Formula C22H36N2O5S M.Wt 440.6
Type of Compound N/A Storage Desiccate at -20°C
Synonyms L700462; MK383
Solubility Limited solubility
Chemical Name (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
SMILES CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O
Standard InChIKey COKMIXFXJJXBQG-NRFANRHFSA-N
Standard InChI InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Tirofiban

DescriptionTirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina. Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml).

References:
[1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. [2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. [3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. [4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. [5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.

Tirofiban Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Tirofiban Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Tirofiban

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2696 mL 11.3482 mL 22.6963 mL 45.3926 mL 56.7408 mL
5 mM 0.4539 mL 2.2696 mL 4.5393 mL 9.0785 mL 11.3482 mL
10 mM 0.227 mL 1.1348 mL 2.2696 mL 4.5393 mL 5.6741 mL
50 mM 0.0454 mL 0.227 mL 0.4539 mL 0.9079 mL 1.1348 mL
100 mM 0.0227 mL 0.1135 mL 0.227 mL 0.4539 mL 0.5674 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Tirofiban

Tirofiban (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.

Featured Products
New Products
 

References on Tirofiban

Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations.[Pubmed:27984753]

Spectrochim Acta A Mol Biomol Spectrosc. 2017 Mar 5;174:326-330.

Apixaban and Tirofiban Hydrochloride are low molecular weight anticoagulants. The two drugs exhibit native fluorescence that allow the development of simple and valid spectrofluorimetric methods for the determination of Apixaban at lambda ex/lambda em=284/450nm and Tirofiban HCl at lambda ex/lambda em=227/300nm in aqueous media. Different experimental parameters affecting fluorescence intensities were carefully studied and optimized. The fluorescence intensity-concentration plots were linear over the ranges of 0.2-6mugml(-1) for apixaban and 0.2-5mugml(-1) for Tirofiban HCl. The limits of detection were 0.017 and 0.019mugml(-1) and quantification limits were 0.057 and 0.066mugml(-1) for apixaban and Tirofiban HCl, respectively. The fluorescence quantum yield of apixaban and Tirofiban were calculated with values of 0.43 and 0.49. Method validation was evaluated for linearity, specificity, accuracy, precision and robustness as per ICH guidelines. The proposed spectrofluorimetric methods were successfully applied for the determination of apixaban in Eliquis tablets and Tirofiban HCl in Aggrastat intravenous infusion. Tolerance ratio was tested to study the effect of foreign interferences from dosage forms excipients. Using Student's t and F tests, revealed no statistically difference between the developed spectrofluorimetric methods and the comparison methods regarding the accuracy and precision, so can be contributed to the analysis of apixaban and Tirofiban HCl in QC laboratories as an alternative method.

Aspiration thrombectomy and intracoronary tirofiban via GuideLiner((R)) catheter for a thrombosed aneurysmal vessel.[Pubmed:28169555]

Future Cardiol. 2017 Mar;13(2):131-135.

A 52-year-old Asian male with no traditional risk factors for coronary artery disease presented with acute coronary syndrome. Coronary angiography showed complete thrombotic occlusion of the left circumflex with a large thrombus burden in the setting of diffuse aneurysmal enlargement of the coronary arteries consistent with antecedent Kawasaki disease. Manual thrombectomy with adjunctive intracoronary Tirofiban was performed utilizing the GuideLiner catheter((R)) (Vascular Solutions, Inc., MN, USA). Stent implantation was deferred. Follow-up imaging 48 h later showed preserved coronary flow and decreased thrombus burden. The GuideLiner catheter, a monorail guiding device, served a novel role in thrombus aspiration and intracoronary medication delivery.

Assessment of platelet function in patients receiving tirofiban early after primary coronary intervention.[Pubmed:28180001]

Interv Med Appl Sci. 2016 Dec;8(4):135-140.

BACKGROUND: Following percutaneous coronary intervention, combined antiplatelet therapy is necessary. Platelet function testing (PFT) has prognostic value and may be applied in the risk assessment of acute coronary syndrome. In case of combined antiplatelet therapy, PFT may require special laboratory methods, as different antiplatelet agents may influence test results. MATERIALS AND METHODS: Platelet functions were measured in stent thrombosis-segment elevation myocardial infarction patients receiving aspirin, clopidogrel, and Tirofiban. The first sampling was obtained immediately after the termination of administration of Tirofiban. The second sample was drawn at a randomly assigned time between 1 and 6 h. The third sampling was done after a minimum of 24 h of Tirofiban cessation. Adenosine diphosphate (ADP)- and thrombin receptor-activating peptide (TRAP)-induced aggregations were measured. RESULTS: Thirty-seven patients were included. Both TRAP- and ADP-induced aggregation values were significantly lower immediately after Tirofiban termination, than after 24 h [TRAP: 26.41 +/- 25.00 units (U) vs. 109.86 +/- 23.69 U, p < 0.0001; ADP: 17.43 +/- 10.10 U vs. 43.92 +/- 23.35 U, p Tirofiban and clopidogrel were 1.34 +/- 0.49 and 1.269 +/- 0.78, respectively. CONCLUSION: ADP-induced residual platelet reactivity is significantly influenced by the presence of concurrent glycoprotein IIb/IIIa inhibitor. In patients receiving combined antiplatelet treatment, ADP-receptor-specific efficiency measurements are valid only after total elimination of GPIIb/IIIa inhibitors.

Description

Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation.

Keywords:

Tirofiban,144494-65-5,L700462; MK383,Natural Products, buy Tirofiban , Tirofiban supplier , purchase Tirofiban , Tirofiban cost , Tirofiban manufacturer , order Tirofiban , high purity Tirofiban

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: